SLC7A11 and neoplasm: Furthermore, an additional mutation at the acetylation site lysine K98 that leads to the complete abrogation of metabolic targets of p53, including SLC7A11 and TIGAR, is severely defective in suppressing tumor growth in mouse xenograft models [56].